Single daily dosing of gentamicin: pharmacokinetic comparison of two dosing methodologies for postpartum endometritis. by Liu, C et al.
Infectious Diseases in Obstetrics and Gynecology 7:133-137 (1999)
(C) 1999 Wiley-Liss, Inc.
Single Daily Dosing of Gentamicin" Pharmacokinetic
Comparison of Two Dosing Methodologies for
Postpartum Endometritis
C. Liu, B. Abate, 1 M. Reyes,2 and B. Gonik3.
1Department of Pharmacy, Detroit Medical Center and Wayne State University, Detroit, MI
eDepartment ofMedicine (Infectious Diseases), Detroit Medical Center and Wayne State University,
Detroit, MI
3Department of Obstetrics and Gynecology, Detroit Medical Center and Wayne State University,
Detroit, MI
ABSTRACT
Objective: We compared the pharmacokinetics of two methods for dosing gentamicin for the treat-
ment of postpartum endometritis with the goal of achieving adequate peak serum concentrations
(>12 mg/L) and prolonged trough levels below 2 mg/L.
Methods: Group-I subjects (n 5) received intravenous gentamicin, 5 mg/kg per total body weight
over 60 min., with a maximum dose of500 mg. Group-II subjects (n 17) were dosed intravenously
according to the following formula: Dose desired peak concentration (fixed at 14 mg/L) * (volume
of distribution, i.e., 0.35 L/kg) * adjusted body weight (in kilograms). Serum gentamicin levels were
obtained 1 hr. and 8-12 hr. after infusion of the second dose. Pharmacokinetic parameters for the
subjects in each group were calculated according to standard formulas.
Results: Subjects in Group I had significantly higher doses and peak drug concentrations (P <
0.01), while in Group II, 76% of patients had peak levels less than desired (<12 mg/L). Both groups
maintained trough levels of <2 mg/L in excess of 12 hr.
Conclusions: Changing to the adjusted body weight formula for Group I, while maintaining a dose
between 4 and 5 mg/kg, would reduce excessive peak concentrations. Using a calculated volume of
distribution of 0.4 L/kg in Group II would improve peak serum concentrations to the desired levels.
Both dosing regimens ensure adequate aminoglycoside pharmacokinetic parameters and avoid the
need for monitoring serial serum drug concentrations, provided the expected clinical response is
also achieved. While the first dosing formula is simpler to calculate, the second dosing formula
allows for more individualized dosing considerations. Infect. Dis. Obstet. Gynecol. 7:133-137,
1999. (C) 1999Wiley-Liss, Inc.
KEY WORDS
endometritis; gentamicin; pharmacokinetics
minoglycosides in combination with ampicil-
lin, clindamycin, or metronidazole represent a
cost-effective treatment for postpartum endometri-
tis, provided excessive serum concentration moni-
toring and nephrotoxicity do not occur. Tradition-
ally, peak concentrations of aminoglycosides >6.0
mg/L have been associated with efficacy, and
trough concentrations <2.0 mg/L have been asso-
ciated with decreased toxicity. 2 Administering
aminoglycosides as single, large, daily doses takes
advantage of several pharmacokinetic (i.e., concen-
tration-dependent killing activity) and pharmaco-
dynamic (i.e., postantibiotic effect) properties.
3
Nephrotoxicity is reported to occur in 5-10% of
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patients receiving aminoglycosides. Major risk fac-
tors for developing nephrotoxicity include older
age, multisystem disease, preexisting renal disease
(estimated by a creatinine clearance <60 mL/min),
and concomitant administration of nephrotoxic
drugs.4 Once-daily dosing has demonstrated equal
efficacy and toxicity when compared with conven-
tional dosing for many serious infections.3
Postpartum patients are often initially under-
dosed with aminoglycosides, presumably due to
their altered physiologic state.5-7 Equilibrium for
creatinine clearance in the postpartum state has
been noted to be reestablished within 2-5 days
following delivery.
8 Administering large, single,
daily doses may represent a strategy to ensure op-
timal peak concentrations and minimize both tox-
icity and the need for therapeutic drug monitor-
ing.9,1
The purpose of this study was to compare the
pharmacokinetics of two methods of single, daily
dosing of aminoglycosides for the treatment of
postpartum endometritis. Goals included 1) achiev-
ing adequate peak serum concentration (12-14 mg/
L) and 2) prolonged period of serum concentration
below 2 mg/L. The data presented are those de-
rived from two independently run obstetric ser-
vices within a single health care system as a part of
a clinical trial to establish optimal dosing regimens.
SUBJECTS AND METHODS
This study was, by design, observational only. Pa-
tients in Group I being treated for a clinical diag-
nosis of postpartum endometritis were prescribed
gentamicin and received a dose of 5 mg/kg per total
body weight once daily (maximum dose 500 mg).
Patients in Group II were dosed according to the
following formula: dose desired peak concentra-
tion (fixed at 14 mg/L) * (volume of distribution,
0.35L/kg) * adjusted body weight (ABW, in kilo-
grams).1 Exclusion criteria included renal dysfunc-
tion (creatinine clearance < 50 mL/min), history of
ototoxicity or nephrotoxicity due to aminoglyco-
sides, and age <16 years. All doses were infused
over 60 min.
All patients were monitored daily by the respec-
tive hospital pharmacy pharmacokinetic services.
Blood samples for drug concentrations were drawn
by venipuncture after the second dose. Peak con-
centration was drawn hr following end of infu-
sion, and a midpoint concentration was drawn 8-12
TABLE I. Patient characteristics
a
Characteristic
Group Group I!
(n=5) (n= 17)
Race: black/white 4/I 13/4
Age (y) 18.8 (I .9) 23.3 (3.6)
Range 17-22 18-33
Total body weight (kg) 80.0 (I 7.7) 88.2 (i 9.7)
Range 56-100 42-118
Ideal body weight 57. (7. I) 52.4 (5.3)
Adjusted body weight 69.3 (3. I) 68.8 (8. I)
Height (in) 65.0 (3.2) 63.2 (2.4)
aResults given as mean (standard deviation). There were no statistically
significant differences between the two groups.
hr following end of infusion. Trough concentration
was calculated using a one-compartment equation
and data from the two levels.
Statistical analysis for characteristics of the pa-
tient population and pharmacokinetic parameters
of the two gentamicin dosing regimens were per-
formed using the unpaired Student t test (P < 0.05).
RESULTS
Five patients were studied using weight-based cal-
culations, and 17 were studied using standard phar-
macokinetic equations. Table presents patient
characteristics for the two groups. No statistical dif-
ferences between the groups were found. Table 2
compares the pharmacokinetic parameters for the
two groups. Peak and trough values were extrapo-
lated using the two measured concentrations. Both
total dose and calculated peak concentrations were
statistically higher for Group I. Figures and 2
graphically represent individual patient data. For
Group I, all patients had peak serum concentra-
tions >12 mg/L; however, 40% had peaks over 20
mg/L. For Group II, 76% of patients had peak con-
centrations less than desired (< 12 rag/L). All pa-
tients in both groups were below 2.0 mg/L for -> 12
hr. Table 3 compares baseline renal function for
patients in both groups. Nearly all patients were
discharged before follow-up creatinine levels were
obtained. No clinically apparent ototoxicity was ob-
served. Although clinical efficacy was not a
planned objective of this study, all patients dem-
onstrated appropriate resolution of their clinical in-
fections in a timely fashion.
DISCUSSION
This observational study demonstrates two meth-
ods of single-daily dosing of aminoglycosides in
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TABLE 2. Pharmacokinetic comparisons of Group
and Group IP
Parameter
Group Group II
(n=5) (n= 17)
Dose (mg)* 404 (97.4) 325 (53.2)
Range 280-500 210-400
Peak (mg/L)** 20.54 (4.12) 12.28 (3.21)
Trough (mg/L) 0.056 (0.037) 0.050 (0.066)
I (h-m) 0.25 (0.01) 0.28 (0.07)
Clearance (mLlmin) 112.SS (3S.79) 130.20 (49.02)
Half-life (hr) 2.62 (0.33) 2.60 (0.70)
VD (L) 26.72 (8.28) 27.80 (6.97)
VD (L/kg) 0.39 (0.10) 0.43 (0.10)
aResults given as mean (standard deviation).
bExtrapolated values.
cVD, volume of distribution.
*P < 0.05.
**P < 0.01.
postpartum patients with endometritis. These data
are consistent with Del Priore et al.9 and Mitra et
al., lz who demonstrated the efficacy of this dosing
regimen compared with traditional thrice-daily ad-
ministration. Additionally, our data compare two
different methodologies for calculating the genta-
micin dose and point out potential areas for im-
provement.
The weight-based method achieved adequate
peak concentrations, although 40% of our study pa-
tients had peaks in excess of 20 mg/L. In the Del
Priore et al.9 study, in which the same 5-mg/kg
calculation was used, the investigators reported
peak concentrations (16.6 mg/L) similar to those in
our study, but did not indicate the number of sub-
jects with peak levels >20 mg/L.
The formula-based method resulted in 76% of
patients reaching peak concentrations below our
target of 12 mg/L. Of note, all of these patients
would have been considered successes in the Del
Priore et al.9 study, since the target peak concen-
tration in that study was >5 mg/L. Although the
general literature acknowledges that the lower
peak concentration is acceptable for gentamicin
dosing, higher values provide an increased likeli-
hood of organism susceptibility. Also of interest is
the fact that we used the well accepted volume of
distribution of 0.35 L/kg in our formula-based cal-
culation,9 whereas the actual calculated mean value
for the group was 0.43 L/kg.
Garrelts 13 compared formula-based and weight-
based once-daily aminoglycoside dosing through a
Bayesian software program using data from a vari-
ety of patients, excluding pregnant and postpartum
women. Patients included 100 adults who were
treated with aminoglycosides for pneumonia, sep-
sis, skin and soft tissue infections, endocarditis, in-
traabdominal infection, and urinary tract infection.
Computer simulation demonstrated that weight-
based calculations for once-daily aminoglycosides
would not reliably produce clinically acceptable se-
rum concentrations or target values. Patients most
likely not to achieve target values included the
young and the elderly and patients with creatinine
clearances below 60 mL/min or above 119 mL/min.
The author recommended individualized regimens
based upon evaluating the peak-to-minimum in-
hibitory concentration ratio, time above minimum
inhibitory concentration, and patient response.
Using Group I’s pharmacokinetic data, we per-
formed a limited simulation to estimate peak
aminoglycoside concentrations by varying patient
weights (ideal body weight and ABW) and drug
doses. These results are displayed in Table 4 and
suggest either 4 mg/kg (based on total body
weight) or 5 mg/kg (based on ABW) would result in
acceptable peak concentrations.
In summary, if a weight-based formula is the
basis for calculating the gentamicin dose, using ei-
ther 4 mg/kg or 5 mg/kg per ABW would achieve
appropriate peak concentrations while avoiding ex-
cessive values for both patients near ideal body
weight and obese patients. Empirically, we would
suggest using a formula-based calculation for pa-
tients requiring more than 500 mg daily dosing,
based on the weight-based method. When using
the formula-based method approach, a volume of
distribution of 0.4 L/kg to calculate the original
dose would increase the peak concentration to de-
sired levels and maintain troughs below 2 mg/L. In
a subsequent group of 10 patients at our institution
dosed according to the formula calculation using
0.4L/kg, all had peaks between 12 and 20 mg/L
and troughs <2 mg/L. Pharmacokinetic parameters
(drug clearance, half-life, and volume of distribu-
tion) were all similar to our original study popula-
tion, and eight of the 10 were above 30% of ideal
body weight.
Both the weight-based and formula-based dos-
ing regimens ensure adequate aminoglycoside
pharmacokinetic parameters and obviate the need
for monitoring serum drug concentrations. Of
course, this is provided that the expected clinical
outcomes are also achieved. While the weight-
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Fig. 2. Gentamicin time-concentration curve in Group-II patients.
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TABLE 3. Baseline renal function
Parameters
Group Group II
(n=5) (n= 17)
Creatinine (mg/dL) 0.85 (0.10) 0.75 (0.15)
Range 0.8-1.0 0.6-I.
Creatinine clearance (mL/min) 94.7 (5.82) 99.21 (20.88)
Range 81.30-100.5 64.67-120.63
aResults given as mean (standard deviation).
TABLE 4. Simulated peak concentrations based on
Group-I patient data
Dose Patients @ IBW Patients > 30% IBW
5 mg/kg TBW 16-17 IJg/mL 19+ IJg/mL
5 mg/kg ABW 16-17 IJg/mL 16-17 IJg/mL
4 mg/kg TBW 12-13 IJg/mL 16+ IJg/mL
4 mg/kg ABW 12-13 IJg/mL 12-13 lug/mL
aTBW, total body weight; IBW, ideal body weight; ABW, adjusted body
weight.
based method is simpler to calculate, the formula-
based method allows for more individualized dos-
ing considerations.
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